AccessibilityHelpAbout Us
Tiziana Life Sciences logo

Tiziana Life Sciences(NASDAQ) TLSA

Market Cap$116.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-40%
5 Year-47%
1 Year-49%
1 Month-15%
$0.91
-6.64%
-0.06Today
Tiziana Life Sciences last closing stock price
MetricPriceDate
Last closeUSD 0.912026-09-18
Tiziana Life Sciences stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-5.67%USD 0.962026-09-11
1 month-15.36%USD 1.072026-08-19
3 month-21.93%USD 1.162026-06-18
Year to date-39.22%USD 1.492025-12-31
1 year-49.12%USD 1.782025-09-18
3 year+34.96%USD 0.672023-09-19
5 year-46.73%USD 1.702021-09-17
Since inception-39.63%USD 1.502021-10-21

Tiziana Life Sciences Financials at a Glance

Market Cap

$116.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$34.95M

EPS (TTM)

-$0.16

P/E Ratio

-5.81

Dividend

$0.00

Beta (Volatility)

0.69 (Low)

Price

$0.91

Volume

414,828.292

Open

$0.97

Previous Close

$0.91

Daily Range

$0.91 - $0.98

52-Week Range

$0.76 - $2.35

Estimated Earnings Date

Mar 3, 2027

TLSA News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Tiziana Life Sciences

Tiziana Life Sciences Ltd is a biotechnology firm focused on developing innovative molecular therapies for various human diseases, particularly in oncology and immunology. The company is advancing several promising programs, including monoclonal antibodies and small molecule inhibitors aimed at treating serious conditions.

Products and Services
  • Foralumab (TZLS-401): A human anti-CD3 monoclonal antibody for autoimmune diseases
  • Milciclib (TZLS-201): A small molecule inhibitor targeting cancer progression
  • Anti-IL6R mAb (TZLS-501): A monoclonal antibody for treating COVID-19 and inflammation
Growth Outlook
  • Strong pipeline with multiple candidates in clinical development stages
  • Focus on expanding therapeutic applications for existing products
  • Potential partnerships to enhance research and development capabilities
Financial Highlights
  • Recent quarterly net income of -$12.8 million, reflecting ongoing R&D investments
  • Cash and short-term investments of $4.01 million as of Q4 2025
  • Current ratio of 8.79, indicating strong liquidity position
Tiziana Life Sciences Ltd is positioned in the biotechnology sector, with a focus on addressing unmet medical needs through its innovative therapies. The company's flagship products, including Foralumab and Milciclib, are designed to tackle complex diseases, which may offer significant market opportunities. The growth outlook remains promising, supported by a robust pipeline and potential collaborations that could enhance the company's research capabilities. Financially, while the company is currently operating at a loss, it maintains a strong liquidity position, which is crucial for funding ongoing research and development efforts. Investors may find Tiziana Life Sciences an intriguing option within the biotechnology landscape, given its innovative approach and potential for future growth.
AI Generated • Sep 19, 2026

Industry

Biotechnology

Sector

Health Care

Employees

10

CEO

Ivor Elrifi, PhD

Website

www.tizianalifesciences.com

Headquarters

London, W1S 2XJ, GB

TLSA Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-125.84%

Return on Capital

-4159.84%

Return on Assets

-36.98%

Earnings Yield

-17.21%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$116.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

128.31M

Volume

414.83K

Avg. Volume

619.95K

Financials (TTM)

Gross Profit

-$421.00K

Operating Income

-$43.36M

EBITDA

-$42.26M

Operating Cash Flow

-$14.07M

Capital Expenditure

-$36.05K

Free Cash Flow

-$14.11M

Cash & ST Invst.

$4.01M

Total Debt

$456.00K

Tiziana Life Sciences Performance Analysis

Tiziana Life Sciences annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
Tiziana Life Sciences sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q42024-12-31N/A
Q22025-06-30N/A
Q42025-12-31N/A
Tiziana Life Sciences annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.15-36.6%
20232023-12-31USD -0.1713.8%
20242024-12-31USD -0.11-35.6%
20252025-12-31USD -0.1640.1%
Tiziana Life Sciences sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-2.0%
Q42024-12-3126.7%
Q22025-06-3027.1%
Q42025-12-31-128.2%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$146.00K

-256.1%

Gross Margin

0.00%

N/A

Market Cap

$116.20MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$11.62M

N/A

Employees

10

N/A

Net Income

-$12.80M

-41.1%

EBITDA

-$12.18M

-42.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$4.01M

+239.0%

Total Debt

$456.00K

+84.6%

Accounts Receivable

$4.26M

-29.7%

Inventory

$0.00

N/A

Long Term Debt

$234.00K

+114.7%

Short Term Debt

$222.00K

+60.9%

Return on Assets

-36.98%

N/A

Return on Invested Capital

-44.82%

N/A

Free Cash Flow

-$6.04M

-77.2%

Operating Cash Flow

-$6.02M

-76.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
COYACoya Therapeutics, Inc.
$4.89+2.73%
PLRXPliant Therapeutics, Inc.
$1.11-1.77%
EXOZeXoZymes, Inc.
$6.44+3.96%
OKYOOKYO Pharma Limited
$1.36+3.03%

Trending Stocks

Symbol / CompanyPricePrice Chg
SPCXSpace Exploration Technologies
$152.71-1.36%
NVDANvidia
$222.27+1.34%
AGNCAGNC Investment Corp.
$9.87-0.40%
INTCIntel
$108.60-0.18%

Questions About TLSA

What is the current price of Tiziana Life Sciences?

Tiziana Life Sciences is trading at $0.91 per share.

What is the 52-week range for Tiziana Life Sciences?

Over the past 52 weeks, Tiziana Life Sciences has traded between $0.76 and $2.35.

How much debt does Tiziana Life Sciences have?

As of the most recent reporting period, Tiziana Life Sciences reported total debt of $456.00K.

How much cash does Tiziana Life Sciences have on hand?

Tiziana Life Sciences reported $4.01M in cash and cash equivalents in its most recent financial results.

What is Tiziana Life Sciences’s dividend yield?

Tiziana Life Sciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services